HGS/GSK's Benlysta stumbles at secondary endpoint of Phase III study
This article was originally published in Scrip
Executive Summary
Human Genome Sciences and GlaxoSmithKline's human monoclonal antibody therapy Benlysta (belimumab), for the treatment of systemic lupus erythematosus (SLE), did not significantly increase patient response rates at 76 weeks compared with placebo – a key secondary endpoint of its BLISS-76 Phase III pivotal trial.